Raising Health

Latest Episodes:

Using AI to Take Bio Farther Jan 11, 2023

Show notes

Jakob Uszkoreit and Vijay Pande discuss all things AI — from Jakob's time at Google Brain, to how humans (and computers) process language, to Inceptive’s belief in the promise of RNA, and how Jakob believes we’re entering inflection point territory.

You can also find a full transcript of this episode on our website.

Additional reading:

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert AI as a Healthcare Superpower Jan 09, 2023

Show notes

The last few months have seen dramatic—almost magical—applications of expert generative AI released to the public. (One of those applications, incidentally, was in editing the sound mix of this episode.)

But what does this mean for healthcare and bio? Vijay Pande, founding partner of a16z Bio + Health, and Marc Andreessen, cofounder of a16z, sat down for a wide-ranging discussion on AI as an additive superpower…for healthcare as well as screenplays, music, and more.

You can also watch the full episode on our YouTube channel: https://www.youtube.com/@a16z.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cultivated Meat: Challenges, Opportunities, Future Dec 15, 2022

Show notes

From initial inspiration in a sci-fi novel to the current state of “designing biology” in cultivated meat, SCiFi Foods cofounder and CEO Joshua March chats with Bio + Health general partner Vijay Pande and editorial lead Olivia Webb about company building, developing and iterating in biology, and what the future of cultivated meat could be.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AI is Here. Now What? Dec 01, 2022

Show notes

AI is here...so why isn't it in every clinic?

Eric Topol talks with a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb about what's taking so long, where AI can help patients and providers the most, what needs to happen to speed up adoption, and whether data or policy is more likely to be an obstacle.

Eric has written extensively about AI in healthcare, including in his most recent book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. He also writes a Substack focused on Covid research, called Ground Truths, linked below. Finally, as a marker of how AI and AI adoption has (and hasn't) changed over the last few years, check out Eric's 2019 interview with Vijay on the a16z Podcast, also linked below.

Ground Truths - https://erictopol.substack.com/
a16z Podcast: AI and Your Doctor, Today and Tomorrow - https://a16z.com/2019/06/13/ai-doctor-deep-medicine-topol/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Regulatory Trends in Telehealth Nov 17, 2022

Show notes

Perhaps no area of healthcare has undergone such a rapid shift as telehealth during the Covid pandemic. But as the world emerges from the public health emergency, it's an open question what will happen with the regulatory aspects of telehealth. Daisy Wolf, deal partner at a16z Bio + Health, talked to Sarah Thomas, general counsel at Sameday Health, about asynchronous telehealth, working with regulators, how counsel thinks about inducements, and more.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Demystifying DC: Opportunities for Collaboration Nov 08, 2022

Show notes

In this episode, a16z Bio+Health general partner Vineeta Agarwala spoke with Bobby Franklin, the president and CEO of the National Venture Capital Association, about whether healthcare can be a bipartisan topic, how regulation can potentially enable care models at scale, and the opportunities for collaboration between DC and startups.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Consolidated Drug Channel and Cash-Pay Drugs Nov 03, 2022

Show notes

What’s up with the drug channel? Julie Yoo, a general partner at a16z Bio+Health, joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, the editorial lead for a16z Bio+Health, to discuss this question. We talk about PBMs, the 340B drug program, some of the startups working within and around the primary drug channel, and whether there’s room for entrepreneurs to build in such a consolidated space.

For additional reading, see some of Adam’s work on his blog, Drug Channels:

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bio x Games: Is a Fun, Therapeutic Game Possible? Oct 20, 2022

Show notes

Can a game be both fun and therapeutic? Vijay Pande, the first employee at Naughty Dog Software and a current Bio+Health general partner at a16z, joins Jon Lai, a Games general partner, and Olivia Webb, the editorial lead for Bio+Health at a16z, to discuss this question. We talk about what constitutes a game, how games and bio can intersect, and what we called the “healthy dessert” problem — the challenge of building a game that’s both fun and therapeutic.

Additional reading discussed during the episode:

a16z general partner Chris Dixon’s essay “Strong and weak technologies”

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carolyn Bertozzi and Degrading Drugs for Problematic Proteins Oct 06, 2022

Show notes

In Bio Eats World's Journal Club episodes, we discuss groundbreaking research articles, why they matter, what new opportunities they present, and how to take these findings from paper to practice. In this episode, Stanford Professor Carolyn Bertozzi and former Bio Eats World host Lauren Richardson discuss the article "Lysosome-targeting chimaeras for degradation of extracellular proteins" by Steven M. Banik, Kayvon Pedram, Simon Wisnovsky, Green Ahn, Nicholas M. Riley & Carolyn R. Bertozzi, published in Nature 584,291–297 (2020).

Many diseases are caused by proteins that have gone haywire in some fashion. There could be too much of the protein, it could be mutated, or it could be present in the wrong place or time. So how do you get rid of these problematic proteins? Dr. Bertozzi and her lab developed a class of drugs -- or modality -- that in essence, tosses the disease-related proteins into the cellular trash can. While there are other drugs that work through targeted protein degradation, the drugs created by the Bertozzi team (called LYTACs) are able to attack a set of critical proteins, some of which have never been touched by any kind of drug before. Our conversation covers how they engineered these new drugs, their benefits, and how they can be further optimized and specialized in the future.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Deploying AI Platforms to Identify Sepsis Jul 21, 2022

Show notes

On this episode, we discuss three recent papers out in Nature Medicine this week, all examining the deployment of Bayesian Health's AI platform in a clinical setting: Two prospective studies focused on clinician adoption and patient outcomes, and one interview-based study focused on clinical experiences with Bayesian’s AI platform, TREWS.

First, we get into detail about the design and results of the prospective studies, then we talk about TREWS in context with other clinical decision support tools. Finally, we talk about clinicians’ attitudes toward adoption.

Featuring Dr. Suchi Saria, PhD, and the CEO of Bayesian Health; Dr. Neri Cohen, MD, PhD, as well as a collaborator with Bayesian Health; and Dr. Vineeta Agarwala, MD, PhD, and a16z general partner. Hosted by Olivia Webb.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected